ZHIFEI-BIOL(SZ:300122) Jin Rong Jie·2025-12-17 10:11Core Viewpoint - The announcement by Zhifei Biological regarding the acceptance of its clinical trial application for a modified Ankara strain monkeypox vaccine marks a significant milestone in the development of domestic monkeypox vaccines in China [1][2]. Group 1: Vaccine Development - Zhifei Biological's subsidiary, Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd., has developed a modified live vaccine for monkeypox, which has been accepted for clinical trial application by the National Medical Products Administration [1]. - The monkeypox vaccine is intended for individuals aged 6 years and older and utilizes a modified live vaccine technology based on the Ankara strain, which is noted for its high safety profile as it does not replicate effectively in human cells [2]. Group 2: Public Health Implications - Monkeypox, caused by the monkeypox virus, poses a significant public health risk, particularly for vulnerable populations such as children, pregnant women, and immunocompromised individuals, who may experience severe complications [2]. - The development and administration of a monkeypox vaccine are critical measures to reduce disease incidence and alleviate public health burdens, especially since no monkeypox vaccine has been approved for use in China as of the announcement date [2]. Group 3: Strategic Importance - The acceptance of the clinical trial application is seen as a key breakthrough for Zhifei Biological in building its portfolio of vaccines for emerging infectious diseases, reflecting the company's focus on innovative technologies and core research efforts [3]. - This progress is expected to enhance the company's long-term sustainable development and contribute to the improvement of China's independent innovation capabilities in major infectious disease prevention [3].